Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932328 | 0.93 | OPRD1 (0.73) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5370140 | 0.93 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5000028 | 0.91 | OPRD1 (0.64) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4923000 | 0.90 | OPRD1 (0.65) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5444619 | 0.89 | OPRD1 (0.76) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5444769 | 0.88 | OPRD1 (0.70) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5727063 | 0.86 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5971267 | 0.86 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL1603684 | 0.86 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5442980 | 0.86 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | claimed |
| EP-1626960-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOID RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004101520-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOD RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626960-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOID RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101520-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOD RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | OPRD1, OPRM1, OPRL1 | OPRD1 1/4885OPRM1 2/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.